Skip to NavigationSkip to content

Enterome bolsters board with new executive appointment

Published on: 12/07/17

Enterome, a clinical-stage company specialising in the personalised treatment of microbiome-related diseases based in Paris, France, has announced the appointment of Mary Thistle to its board as a non-Executive Director.

Thistle currently serves as the Chief Operating Officer of Dimension Therapeutics, a metabolic and rare disease specialist biopharmaceutical firm focusing on ailments of the liver, which she joined in 2015. Before this, she held the role of Senior Vice President, Business Development at Cubist Pharmaceuticals, and it was here that she oversaw the execution of four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals – two companies which were acquired by Cubist Pharmaceuticals in 2013, which was itself acquired by MSD for $9.5 billion a year later.

“We are pleased to welcome Mary to the Enterome Board,” commented Georges Gemayel, Non-Executive Chairman of Enterome. “This is an exciting period for the Company and we are confident that Mary’s experience will be a valuable asset assisting us to achieve our goals.”

Thistle herself added: “I am honoured to join the Enterome board and look forward to working with the management team to help the Company capitalize on its world-leading position in understanding the microbiome to create novel therapies for microbiome-related diseases.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches